Olfactomedin 4 is a marker for progression of cervical neoplasia

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 367-372

  Yu, Li ^a   He, Mian ^b   Yang, Zheng ^a   Chen, Guidong ^a   Li, Mengzhen ^c   Wang, Liantang ^a   Chen, Shangwu ^c  

^a Departments of Pathology   (China)

^b First Affiliated Hospital   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia (CIN); Immunohistochemistry; Olfactomedin 4

Indexed keywords

OLFACTOMEDIN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 79956085883     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820866fe     Document Type: Article

References (25)

1. Snyder DA, Rivers AM, Yokoe H, et al. Olfactomedin: purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry. 1991;30:9143-9153.
2. Zeng LC, Han ZG, Ma WJ. Elucidation of subfamily segregation and intramolecular coevolution of the olfactomedin-like proteins by comprehensive phylogenetic analysis and gene expression pattern assessment. FEBS Lett. 2005;579:5443-5453.
3. Tomarev SI, Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology. Mol Neurobiol. 2009;40: 122-138.
4. Zhang X, Huang Q, Yang Z, et al. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res. 2004;64: 2474-2481. (Pubitemid 38523902)
5. Zhang J, Liu WL, Tang DC, et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 2002;283:83-93. (Pubitemid 34178512)
6. Liu W, Zhu J, Cao L, et al. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology. 2007;51:157-165. (Pubitemid 47084003)
7. Takenawa H, Kurosaki M, Enomoto N, et al. Differential gene-expression profiles associated with gastric adenoma. Br J Cancer. 2004;90:216-223. (Pubitemid 38174964)
8. Aung PP, Oue N, Mitani Y, et al. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene. 2006;25:2546-2557.
9. Oue N, Aung PP, Mitani Y, et al. Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology. 2005;69:17-22. (Pubitemid 41433537)
10. Oue N, Sentani K, Noguchi T, et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009;125:2383-2392.
11. Koshida S, Kobayashi D, Moriai R, et al. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci. 2007;98:315-320. (Pubitemid 46195600)
12. Wentzensen N, Wilz B, Findeisen P, et al. Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. Int J Oncol. 2004;24:987-994.
13. Liu W, Liu Y, Zhu J, et al. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 2008;14:1041-1049. (Pubitemid 351302549)
14. Kim KK, Park KS, Song SB, et al. Up regulation of GW112 Gene by NFkappaB promotes an antiapoptotic property in gastric cancer cells. Mol Carcinog. 2010;49:259-270.
15. Kobayashi D, Koshida S, Moriai R, et al. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 2007;98:334-340. (Pubitemid 46195603)
16. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
17. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942-953. (Pubitemid 39273789)
18. Halloush RA, Akpolat I, Jim Zhai Q, et al. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer. 2008;114: 474-480.
19. Aoyama C, Liu P, Ostrzega N, et al. Histologic and immunohistochemical characteristics of neoplastic and nonneoplastic subgroups of atypical squamous lesions of the uterine cervix. Am J Clin Pathol. 2005;123:699-706. (Pubitemid 40586487)
20. Yu L, Wang L, Li M, et al. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010;59:1021-1028.
21. Yu L, Wang L, Zhong J, et al. Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol. 2010;118:47-55.
22. Liu W, Chen L, Zhu J, et al. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res. 2006;312:1785Y1797. (Pubitemid 44218717)
23. Kisseljov F, Sakharova O, Kondratjeva T. Cellular and molecular biological aspects of cervical intraepithelial neoplasia. Int Rev Cell Mol Biol. 2008;271:35-95.
24. Shai A, Pitot HC, Lambert PF. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 2010;70:5064-5073.
25. Fonseca-Moutinho JA, Cruz E, Carvalho L, et al. Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer. 2004;14:911-920. (Pubitemid 39238179)